Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Impedimed Limited ( (AU:IPD) ) has provided an announcement.
Impedimed Limited has notified the ASX that certain equity instruments on issue have lapsed, including 4,742,000 options with various expiry dates and prices, and 108,079 performance rights, all of which ceased on 31 December 2025 after the conditions attached to them were not met or became incapable of being satisfied. The cancellation of these conditional rights modestly reduces the company’s potential future share dilution, clarifies its capital structure for investors, and may reflect performance or milestone criteria that were not achieved under existing incentive arrangements.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.07 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
More about Impedimed Limited
Average Trading Volume: 1,194,115
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$69.3M
For a thorough assessment of IPD stock, go to TipRanks’ Stock Analysis page.